Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 20;9(1):1794423.
doi: 10.1080/2162402X.2020.1794423.

Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors

Romain Daillère  1 , Bertrand Routy  2   3 , Anne-Gaëlle Goubet  4   5 , Alexandria Cogdill  4   5 , Gladys Ferrere  4   5 , Carolina Alves-Costa Silva  4   5 , Aurélie Fluckiger  4   5 , Pierre Ly  4   5 , Yacine Haddad  4   5 , Eugenie Pizzato  4   5 , Cassandra Thelemaque  4   5 , Marine Fidelle  4   5 , Marine Mazzenga  4   5 , Maria Paula Roberti  4   5   6 , Cléa Melenotte  4   7 , Peng Liu  4   8   9 , Safae Terrisse  4   5 , Oliver Kepp  4   8   9 , Guido Kroemer  4   8   9   10   11   12 , Laurence Zitvogel  4   5   6   7   11 , Lisa Derosa  4   5
Affiliations
Review

Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors

Romain Daillère et al. Oncoimmunology. .

Abstract

Accumulating evidence from preclinical studies and human trials demonstrated the crucial role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade. In summary, it appears that a diverse intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota composition that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. In this review, we explore preclinical and translational studies highlighting how eubiotic and dysbiotic microbiota composition can affect progression-free survival in cancer patients.

Keywords: Anticancer therapeutics; Cancer; gut microbiota.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Key bacteria safely boosting the efficacy of anticancer therapeutics in vivo.
See this image and copyright information in PMC

References

    1. Pardoll D. Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol. 2015;42(4):523–11. doi:10.1053/j.seminoncol.2015.05.003. - DOI - PMC - PubMed
    1. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain J-F, Testori A, Grob -J-J, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. doi:10.1056/NEJMoa1104621. - DOI - PubMed
    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643. - DOI - PMC - PubMed
    1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa1411087. - DOI - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690. - DOI - PMC - PubMed

Substances